ALK and lung adenocarcinoma: The findings of this study suggest that first‐line crizotinib treatment resulted in significantly higher response rates and a longer PFS in comparison with first‐line standard chemotherapy in Chinese patients with ALK‐positive, advanced lung adenocarcinoma.